ADC Therapeutics CEO Ameet Mallik (L) and CMO Mohamed Zaki
May 6, 2024 02:41 PM EDTUpdated May 9, 06:26 AM
Financing
R&D

ADC Ther­a­peu­tics re­veals topline Zyn­lon­ta da­ta, $105M stock of­fer­ing

Katherine Lewin

News Reporter

ADC Ther­a­peu­tics an­nounced a $105 mil­lion of­fer­ing af­ter shar­ing what it called pos­i­tive topline da­ta from a Phase 2 tri­al of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times